Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine in Women With Operable Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histological confirmation of primary invasive breast cancer~* Stage I-III operable breast cancer.~* Primary tumor must be greater than or equal to 2cm by radiographic imaging or palpitation~* Women greater than 18 years of age~* ECOG performance status 0-1~* WBC \> 4000/mm3~* Platelet count \> 100,000/mm3~* SGOT \< 2x ULN~* Calculated creatinine clearance \> 50ml/min~Exclusion Criteria:~* Evidence of metastatic (stage IV) cancer on physical exam or any diagnostic study.~* Pregnant or breast-feeding women~* Inflammatory breast cancer~* HER2 positive disease~* History of hypersensitivity to a 5-FU or known dihydropyrimidine dehydrogenase (DPD) deficiency~* Uncontrolled intercurrent illness~* Prior history of breast cancer are ineligible except: diagnosed at least 2 years ago; present cancer is not in previously irradiated breast; no prior chemotherapy in the past 5 years; no prior high-dose chemotherapy with stem cell or bone marrow transplant.~* Excisional biopsy performed prior to enrollment~* Uncontrolled coagulopathy~* Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).